Clinical Trial Update: Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the SGLT2 inhibitor dapagliflozin in adults with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: Rehab Werida | Conditions: Nonalcoholic Fatty Liver Disease, Type 2 Diabetes | Phase 4 | Status: COMPLETED